array(3) { ["company_details"]=> array(13) { ["name"]=> string(25) "ROCHE DIAGNOSTICS LIMITED" ["slug"]=> string(34) "ef866-gb-roche-diagnostics-limited" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/5ce04174-8fff-4069-9bd1-2ef80ada854c" ["description"]=> string(1583) "Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com/global/en Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation" ["address_street"]=> string(14) "Charles Avenue" ["address_place"]=> string(12) "BURGESS HILL" ["address_region"]=> NULL ["founding_date"]=> string(10) "1956-09-14" ["website_domain"]=> string(9) "roche.com" ["website_url"]=> string(29) "https://diagnostics.roche.com" ["industry_codes"]=> array(1) { [0]=> string(43) "Business Services, Not Elsewhere Classified" } ["employee_count"]=> int(658) ["article_count"]=> int(3529) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(152) "Stock market ticker: Swiss stock exchange starts new week with attempted recovery - Further losses for Roche - Analyst sees SMI shares 15 percent higher" ["snippet_en"]=> string(106) "The Swiss stock exchange started the new trading week on Monday with a countermovement to Friday's losses." ["url"]=> string(181) "https://www.cash.ch/news/top-news/borsen-ticker-schweizer-borse-startet-mit-erholungsversuch-in-neue-woche-weitere-verluste-fur-roche-analyst-sieht-smi-titel-15-prozent-hoher-700028" ["image_url"]=> string(78) "https://images.businessradar.com/articles/1e1aab8e-1d54-401a-9918-c14a4cb84478" ["source"]=> string(7) "cash.ch" ["publication_date"]=> string(10) "2024-04-08" ["categories"]=> array(4) { [0]=> string(15) "Market Movement" [1]=> string(12) "Stock Market" [2]=> string(12) "Going Public" [3]=> string(24) "Quarterly/Annual Figures" } } [1]=> array(7) { ["title_en"]=> string(136) "F. Hoffmann-La Roche Ltd: Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19" ["snippet_en"]=> string(200) "Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going" ["url"]=> string(201) "https://www.finanznachrichten.de/nachrichten-2024-04/62029514-f-hoffmann-la-roche-ltd-roche-sales-increase-by-2-cer-in-first-quarter-with-both-divisions-growing-in-high-single-digit-ex-covid-19-399.htm" ["image_url"]=> string(78) "https://images.businessradar.com/articles/776e525e-dc33-49e4-9628-be02297d2bc2" ["source"]=> string(20) "finanznachrichten.de" ["publication_date"]=> string(10) "2024-04-06" ["categories"]=> array(3) { [0]=> string(8) "Epidemic" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(24) "Quarterly/Annual Figures" } } [2]=> array(7) { ["title_en"]=> string(52) "JPMORGAN upgrades ROCHE HOLDINGS AG to 'Underweight'" ["snippet_en"]=> string(273) "April 5, 2024 - The US bank JPMorgan has left the rating for Roche at 'Underweight' with a price target of 210 francs ahead of figures for the first quarter. The pharmaceutical company is likely to fall slightly short of market expectations, wrote analyst Richard Vosser..." ["url"]=> string(96) "https://www.wallstreet-online.de/nachricht/17956414-jpmorgan-stuft-roche-holdings-ag-underweight" ["image_url"]=> string(78) "https://images.businessradar.com/articles/bea16ee2-e486-4e03-8a9a-7c722a3622d3" ["source"]=> string(20) "wallstreet-online.de" ["publication_date"]=> string(10) "2024-04-05" ["categories"]=> array(4) { [0]=> string(31) "Financial Update/Profit Warning" [1]=> string(12) "Stock Market" [2]=> string(24) "Quarterly/Annual Figures" [3]=> string(24) "Stock Research & Ratings" } } [3]=> array(7) { ["title_en"]=> string(81) "Roche Bobois: improvement in annual operating performance, dividend of 2.25 euros" ["snippet_en"]=> string(147) "Roche Bobois reports a solid 2023 financial year and will propose at the next General Meeting the payment of a dividend of 2.25 euros per share,..." ["url"]=> string(152) "https://www.boursier.com/actions/actualites/news/roche-bobois-amelioration-de-la-performance-operationnelle-annuelle-dividende-de-2-25-euros-924930.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f93f9871-476f-4cbf-91a2-7625183e6dbf" ["source"]=> string(12) "boursier.com" ["publication_date"]=> string(10) "2024-03-26" ["categories"]=> array(4) { [0]=> string(31) "Financial Update/Profit Warning" [1]=> string(12) "Stock Market" [2]=> string(24) "Quarterly/Annual Figures" [3]=> string(21) "Shareholders Feedback" } } [4]=> array(7) { ["title_en"]=> string(114) "Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update" ["snippet_en"]=> string(201) "Advanced OpRegen® For Dry AMD in Phase 2a Study in Collaboration with Roche and Genentech Closed $14 Million Registered Direct Offering OPC1 Investigational New Drug Amendment Cleared; New Clinical..." ["url"]=> string(147) "https://pharmaceuticaldaily.com/lineage-cell-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-update/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/c2490fed-71aa-4fd4-8b98-d043d6300857" ["source"]=> string(23) "pharmaceuticaldaily.com" ["publication_date"]=> string(10) "2024-03-08" ["categories"]=> array(2) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(13) "Collaboration" } } [5]=> array(7) { ["title_en"]=> string(101) "Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023" ["snippet_en"]=> string(286) "Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2023." ["url"]=> string(93) "https://finance.yahoo.com/news/poseida-therapeutics-provides-updates-financial-210500347.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/9a656bcb-d327-44f2-bfcf-f3573ab37683" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2024-03-07" ["categories"]=> array(4) { [0]=> string(15) "Deals & Tenders" [1]=> string(31) "Financial Update/Profit Warning" [2]=> string(24) "Quarterly/Annual Figures" [3]=> string(13) "Collaboration" } } [6]=> array(7) { ["title_en"]=> string(59) "Switzerland: Roche is considering selling lung drug Esbriet" ["snippet_en"]=> string(124) "In 2023, sales of the drug fell by 70 percent. That's why the Swiss pharmaceutical giant is thinking about selling the drug." ["url"]=> string(97) "https://www.handelszeitung.ch/newsticker/roche-erwagt-verkauf-von-lungenmedikament-esbriet-687445" ["image_url"]=> string(78) "https://images.businessradar.com/articles/a57a8f2b-ce38-4ea6-915f-6ccad5bd2357" ["source"]=> string(17) "handelszeitung.ch" ["publication_date"]=> string(10) "2024-02-27" ["categories"]=> array(1) { [0]=> string(24) "Quarterly/Annual Figures" } } [7]=> array(7) { ["title_en"]=> string(101) "The rises in the European and Wall Street stock markets are achieved with half of the negative values" ["snippet_en"]=> string(327) "The main stock exchanges on this and the other side of the Atlantic not only accumulate profits for the year, but their prices reach highs that have not been seen before in their stock market history. These figures are entirely encouraging if the general calculation of these indices is taken into account, but at the same time" ["url"]=> string(169) "https://www.eleconomista.es/mercados-cotizaciones/noticias/12692573/02/24/las-subidas-en-bolsa-de-europa-y-wall-street-se-logran-con-la-mitad-de-valores-en-negativo.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/3383ff7a-5819-406a-a8c5-9f59297ff4d9" ["source"]=> string(15) "eleconomista.es" ["publication_date"]=> string(10) "2024-02-26" ["categories"]=> array(6) { [0]=> string(18) "General Investment" [1]=> string(15) "Market Movement" [2]=> string(12) "Stock Market" [3]=> string(19) "Economic Conditions" [4]=> string(24) "Quarterly/Annual Figures" [5]=> string(9) "Investors" } } [8]=> array(7) { ["title_en"]=> string(55) "Roche cutting 345 jobs in product development – media" ["snippet_en"]=> string(251) "ZURICH (Reuters) - Roche is cutting 345 jobs, Swiss website Muula reported, as the drugs company responds to lower profit posted for 2023 and a more cautious outlook for the year ahead. The jobs will go in the product development area, and correspo..." ["url"]=> string(80) "https://whbl.com/2024/02/09/roche-cutting-345-jobs-in-product-development-media/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/b6571d0b-2d09-4a7c-b59e-ef4ad3764aeb" ["source"]=> string(8) "whbl.com" ["publication_date"]=> string(10) "2024-02-09" ["categories"]=> array(6) { [0]=> string(12) "Staff hiring" [1]=> string(15) "Labor Practices" [2]=> string(7) "Layoffs" [3]=> string(31) "Financial Update/Profit Warning" [4]=> string(22) "Business Restructuring" [5]=> string(24) "Quarterly/Annual Figures" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(219) } [1]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(206) } [2]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(191) } [3]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(155) } [4]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(154) } [5]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(149) } [6]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(143) } [7]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(140) } [8]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(112) } [9]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(103) } [10]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(102) } [11]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(101) } [12]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(96) } [13]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(93) } [14]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(86) } [15]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(69) } [16]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(65) } [17]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(64) } [18]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(64) } [19]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(49) } [20]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(42) } [21]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(41) } [22]=> array(2) { ["name"]=> string(12) "Going Public" ["count"]=> int(41) } [23]=> array(2) { ["name"]=> string(19) "Economic Conditions" ["count"]=> int(39) } [24]=> array(2) { ["name"]=> string(12) "Staff hiring" ["count"]=> int(34) } [25]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(34) } [26]=> array(2) { ["name"]=> string(10) "New Market" ["count"]=> int(32) } [27]=> array(2) { ["name"]=> string(20) "Business Development" ["count"]=> int(32) } [28]=> array(2) { ["name"]=> string(16) "Customer Welfare" ["count"]=> int(32) } [29]=> array(2) { ["name"]=> string(7) "Layoffs" ["count"]=> int(31) } } } ef866-gb-roche-diagnostics-limited